No Data
Kehua Biotech: 2024 Annual Performance Forecast
Shanghai Kehua Bio-engineering (002022.SZ) has issued a profit warning, expecting a net loss of 0.53 billion yuan to 0.65 billion yuan for the 2024 fiscal year.
Shanghai Kehua Bio-engineering (002022.SZ) released its 2024 performance forecast, expecting the full-year attributable profit to the Shareholder of the listed company...
Shanghai Kehua Bio-engineering (002022.SZ) has been approved by the National Medical Products Administration: new test kit for Helicobacter pylori antibody detection.
On January 1, Gelonghui reported that Shanghai Kehua Bio-engineering (002022.SZ) announced that it recently received the medical instruments registration certificate issued by the National Medical Products Administration (in vitro diagnostic reagents). The specific product is "Helicobacter pylori antibody detection kit (latex immunoturbidimetry method)", with registration certificate number National Medical Device Approval 20243402655, valid from December 30, 2024, to December 29, 2029. This product is used for the qualitative detection of Helicobacter pylori antibodies in human serum and plasma samples.
Shanghai Kehua Bio-EngineeringLtd (SZSE:002022 Shareholders Incur Further Losses as Stock Declines 11% This Week, Taking Three-year Losses to 55%
Kehua Tech Recognized in BNEF's Latest Bankability Survey
Kehua Ranked No.4 in the Global Modular UPS Market Share for Two Consecutive Years
Investors Don't See Light At End Of Shanghai Kehua Bio-Engineering Co.,Ltd's (SZSE:002022) Tunnel And Push Stock Down 26%
